Literature DB >> 23471696

Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.

Gianluca Tamagno1, Kieran Sheahan, Stephen J Skehan, Justin G Geoghegan, David Fennelly, Conor D Collins, Donal Maguire, Oscar Traynor, David P Brophy, Colin Cantwell, Niall Swan, Lisa McGowan, Dermot O'Toole, Donal O'Shea.   

Abstract

According to the international guidelines, a multidisciplinary approach is currently advised for the optimal care of patients with a gastroenteropancreatic neuroendocrine tumor (GEP NET). In our institution (tertiary care center), a systematic multidisciplinary approach was established in May 2007. In this study, we have aimed to assess the initial impact of establishing a systematic multidisciplinary approach to the management of GEP NET patients. We have collected and compared the biochemical, imaging, and pathological data and the therapeutic strategies in GEP NET patients diagnosed, treated, or followed-up from January 1993 to April 2007 versus GEP NET patients attending our institution after the multidisciplinary approach starting, from May 2007 to October 2008. Data of 91 patients before and 42 patients after the establishment of the multidisciplinary approach (total: 133 consecutive GEP NET patients) have been finally collected and analyzed. Before the establishment of the multidisciplinary approach, a lack of consistency in the biochemical, imaging, and pathological findings before treatment initiation as well as during follow-up of GEP NET patients was identified. These inconsistencies have been reduced by the systematic multidisciplinary approach. In addition, the therapeutic management of GEP NET patients has been altered by the multidisciplinary approach and became more consistent with recommended guidelines. We think that a systematic multidisciplinary approach significantly impacts on GEP NET patient care and should be established in all centers dealing with these tumors.

Entities:  

Mesh:

Year:  2013        PMID: 23471696     DOI: 10.1007/s12020-013-9910-5

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  25 in total

Review 1.  Carcinoid heart disease.

Authors:  Sanjeev Bhattacharyya; Joseph Davar; Gilles Dreyfus; Martyn E Caplin
Journal:  Circulation       Date:  2007-12-11       Impact factor: 29.690

2.  Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?

Authors:  Kjell Öberg
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

3.  Proceedings of the 3rd ENETS Consensus Conference on Guidelines for the Standard of Care in Neuroendocrine Tumors, Palma de Mallorca, Spain, 2007.

Authors: 
Journal:  Neuroendocrinology       Date:  2009       Impact factor: 4.914

Review 4.  Somatostatin and somatostatin analogues: diagnostic and therapeutic uses.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Curr Opin Oncol       Date:  2002-01       Impact factor: 3.645

Review 5.  Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment.

Authors:  Kjell Oberg
Journal:  Curr Opin Oncol       Date:  2005-07       Impact factor: 3.645

Review 6.  Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

Authors:  R Garcia-Carbonero; J Capdevila; G Crespo-Herrero; J A Díaz-Pérez; M P Martínez Del Prado; V Alonso Orduña; I Sevilla-García; C Villabona-Artero; A Beguiristain-Gómez; M Llanos-Muñoz; M Marazuela; C Alvarez-Escola; D Castellano; E Vilar; P Jiménez-Fonseca; A Teulé; J Sastre-Valera; M Benavent-Viñuelas; A Monleon; R Salazar
Journal:  Ann Oncol       Date:  2010-02-05       Impact factor: 32.976

Review 7.  Carcinoid tumors and fibrosis: an association with no explanation.

Authors:  Irvin M Modlin; Michael D Shapiro; Mark Kidd
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

8.  The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors.

Authors:  Ursula Ploeckinger; Guenter Kloeppel; Bertram Wiedenmann; Ruediger Lohmann
Journal:  Neuroendocrinology       Date:  2009-09-23       Impact factor: 4.914

9.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

10.  Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.

Authors:  G B Turner; B T Johnston; D R McCance; A McGinty; R G P Watson; C C Patterson; J E S Ardill
Journal:  Gut       Date:  2006-03-23       Impact factor: 23.059

View more
  4 in total

Review 1.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

2.  ⁶⁸Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors.

Authors:  Jan Calissendorff; Anders Sundin; Henrik Falhammar
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

3.  Management of neuroendocrine neoplasms: conformity with guidelines in and outside a center of excellence.

Authors:  Carole Morin; Keo-Morakort Benedetto; Agathe Deville; Laurent Milot; Aurélie Theillaumas; Valérie Hervieu; Mathieu Pioche; Gilles Poncet; Julien Forestier; Laurent François; Francoise Borson-Chazot; Mustapha Adham; Catherine Lombard-Bohas; Thomas Walter
Journal:  Endocr Connect       Date:  2022-06-15       Impact factor: 3.221

4.  Management and Follow-up of Patients with a Bronchial Neuroendocrine Tumor in the Last Twenty Years in Ireland: Expected Inconsistencies and Unexpected Discoveries.

Authors:  Asta Agasarova; Clare Harnett; Niall Mulligan; Muhammad Shakeel Majeed; Alberto Caimo; Gianluca Tamagno
Journal:  Int J Endocrinol       Date:  2018-08-29       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.